GT Biopharma’s pipeline of therapies have attracted several industry heavyweights that hail from companies like Pfizer (PFE), Chase Pharmaceuticals, Sanofi (SNY), and Deutsche Bank (DB). GT Biopharma’s pipeline includes numerous treatments in or about to be in Phase II trials as well as other treatments in preclinical trials.